

![]() |
Haematological malignancies following temozolomide treatment for paediatric high-grade glioma |
|
Authors | ![]() | |
Published in | European Journal of Cancer. 2017, vol. 81, p. 1-8 | |
Abstract | Temozolomide (TMZ) is widely used in high-grade glioma (HGG). There is a major concern of treatment-induced secondary haematological malignancies (SHMs). Due to the poor overall survival of HGG patients, the true incidence is yet elusive. Thus, the aim of this study was to determine the risk of SHMs following TMZ in paediatric HGG. | |
Keywords | Adolescent — Antineoplastic Agents — Alkylating/adverse effects — Austria/epidemiology — Child — Child — Preschool — Dacarbazine/adverse effects/analogs & derivatives — Female — Follow-Up Studies — Germany/epidemiology — Glioma/drug therapy — Hematologic Neoplasms/chemically induced/epidemiology — Humans — Incidence — Infant — Kaplan-Meier Estimate — Male — Switzerland/epidemiology | |
Identifiers | PMID: 28586748 | |
Full text | ||
Structures | ||
Research group | Oncologie et hématologie pédiatrique (907) | |
Citation (ISO format) | KARREMANN, Michael et al. Haematological malignancies following temozolomide treatment for paediatric high-grade glioma. In: European Journal of Cancer, 2017, vol. 81, p. 1-8. doi: 10.1016/j.ejca.2017.04.023 https://archive-ouverte.unige.ch/unige:107413 |